Up to 85 Percent of People with Uncommon Forms of Alzheimer’s Would Not Qualify for the New Drugs, Study Finds

A Neurology study found 70% to 85% of atypical Alzheimer’s patients would not meet lecanemab or donanemab eligibility criteria. Why it happens.

Have A Referral?